Project Grant R61AG094667
- This $2,220,145 federal Project Grant award, funded by the National Institute on Aging under the Aging Research program (CFDA 93.866), aims to optimize and develop novel cell-type-selective adeno-associated virus (AAV) vector technologies to study disease-relevant cell types and neural circuits in mouse models of aging and Alzheimer's disease. The key products and services to be delivered include: Developing enhanced AAV vectors that can genetically target and manipulate specific brain cell...
- The National Institute on Aging (NIA) awarded a $842,175 Project Grant under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on December 15, 2024, will fund research to explore the role of the NOX2 enzyme in mediating Alzheimer's disease (AD) pathologies, including network hyperactivity, glucose hypometabolism, and accumulation of amyloid-beta and tau proteins. The research aims to assess the therapeutic efficacy of a novel...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $804,450 Project Grant to the J. David Gladstone Institutes in San Francisco, CA. This grant, awarded on June 1, 2025, will fund a research project titled "Targeting NELL2 and GABAergic Dysfunction to Mitigate APOE4-Driven Pathogenesis in Alzheimer's Disease." The project aims to investigate the role of the APOE4 gene and its interaction with sex and aging in contributing to...
- The National Institute on Aging (NIA) awarded a $4,276,054 Project Grant under the Aging Research federal grant program (CFDA 93.866) to The Regents of the University of California, San Francisco (UCSF) on September 1, 2024. The project aims to develop mathematical models to quantitatively test and validate hypotheses regarding the selective vulnerability of genes, cells, and neural networks in mouse models of Alzheimer's disease (AD) tauopathy. The research will leverage two enabling...
- This federal Project Grant award of $817,357 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to harness novel machine learning approaches for behavioral segmentation and brain signal integration in humanized models of Alzheimer's disease. The key products and services to be delivered under this grant include: Further validation of the grantee's "Variational Animal Motion Embedding (VAME)" machine learning platform for comprehensive behavioral phenotyping of...
- This $1,425,000 project grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research into neuronal senescence and inflammation in Alzheimer's disease. The Salk Institute for Biological Studies will study the interaction between cellular senescence and inflammation in induced neurons derived from Alzheimer's patients and healthy aged controls. Researchers will examine differences in gene expression and epigenetic...
- This federal Project Grant award of $3,221,450.00 from the National Institute on Aging (CFDA 93.866 Aging Research) supports research to define how neuronal hyperexcitability in the retrosplenial cortex (RSC) contributes to the development of Alzheimer's disease (AD)-related behavioral deficits in mouse models. The research aims to determine the effect of inhibiting RSC layer 5 cells on spatial memory and navigation, as well as when hyperexcitability emerges in these cells across different AD...
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,083,046 Project Grant under the Aging Research program (CFDA 93.866) to The Johns Hopkins University. The grant, running from August 1, 2025 to July 31, 2027, will support the development of novel adeno-associated viruses (AAVs) to selectively manipulate oligodendrocyte precursor cells (OPCs) in the central nervous system. The project aims to test the hypothesis that reactive...
- The National Institute on Aging (NIA) awarded a $442,357 Project Grant under the Aging Research program (CFDA 93.866) to the Research Foundation of the City University of New York (RFCUNY) on December 15, 2024. The grant aims to elucidate the molecular mechanisms that give rise to functionally neurodegenerative microglia, the brain's primary innate immune cells, which have been implicated as major determinants of Alzheimer's disease (AD) risk. The research will leverage novel mouse models and...
- The National Institute on Aging (NIA), under the Federal Aging Research program (CFDA 93.866), awarded a $245,148 project grant to Eyenexo LLC to develop an automated rodent behavior testing system for non-invasively assessing early-stage Alzheimer's disease (AD). The project aims to develop a behavior biomarker that can differentiate AD from normal aging by studying defensive behaviors triggered by looming stimuli, which are linked to early AD pathology in the midbrain region. The 2-year...
The National Institute on Aging (NIA) awarded a $1,459,072 project grant to the J. David Gladstone Institutes under the Aging Research Federal Grant Program (CFDA 93.866) to monitor and manipulate inhibitory interneuron cell populations in mouse models of Alzheimer's disease. The 2-year project aims to use dual cell-type-specific enhancer-associated adeno-associated viruses (enhancer-AAVs) to independently monitor and control parvalbumin (PVALB) and somatostatin (SST) inhibitory interneurons in order to assess their contribution to Alzheimer's-related brain network dysfunction, including oscillatory deficits, network hypersynchrony, and associated behavioral changes. The project leverages machine learning techniques to evaluate the efficacy of the cell-type-specific manipulations in the Alzheimer's disease mouse models.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.5m | 7/29/25 |